Stephane Bidet on LinkedIn: Full press release in English | 22 comments
Sanofi on LinkedIn: Press Release: Sanofi announces agreement for potential first-in-class… | 26 comments
Press Release: Sanofi Enters Next Chapter of Play to Win
New Eloxatin® (oxaliplatin injection) Prescribing Information ... - Sanofi
Sanofi on LinkedIn: We aim to be an industry-leading company in Immunology. We are announcing… | 17 comments
Sanofi on X: "#SanofiActs against #COVID19 Read more on our latest collaboration with @TranslateBio, investigating multiple candidates, with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development. https://t.co/C8B5bsy7DH
STADA and Sanofi strike CHC distribution agreement | STADA
Media, press releases, news and media resources
How To Write A Press Release: Free Templates, 45 Examples, & Formatting Tips
Sanofi-aventis press release ClikSTAR® A New Reusable Insulin ...
Press release Sanofi-aventis
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases | Business Wire
Sanofi-aventis confirms its intent to reinforce its presence in the ...
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery – Atomwise
Behind the collapse of Sanofi's Fedratinib… a TSR Special Report | MPNforum Magazine
PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC
Sanofi joins scleroderma trial initiative as 1st partner
Press Release: Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio
Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal | Reuters
Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care | BioSpace
Q1A. Using the example (PDF) provided and the course | Chegg.com
STADA further grows European Consumer Healthcare portfolio | STADA
Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as #
Logo of Pharmaceutical French group Sanofi-Aventis during a press conference to present the full-year 2005 results. Sanofi-Aventis announced a serie of positive drug research developments, in Paris, on February 24, 2006. Photo
Industry's IL-2 Struggles Continue as Sanofi Drops Program | BioSpace
